Ribavirin Plasma Concentration Predicts Sustained Virological Response to Peginterferon Alfa 2a Plus Ribavirin in Previously Treated HCV-HIV–Coinfected Patients-Reference-Cited by-同舟云学术

Ribavirin Plasma Concentration Predicts Sustained Virological Response to Peginterferon Alfa 2a Plus Ribavirin in Previously Treated HCV-HIV–Coinfected Patients

Published:2009-11 Issue:3 Volume:52 Page:428-430
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Breilh Dominique,Djabarouti Sarah,Trimoulet Pascale,Bail Brigitte Le,Dupon Michel,Ragnaud Jean-Marie,Fleury Hervé,Saux Marie-Claude,Thiébaut Rodolphe,Chêne Geneviève,Neau Didier

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference10 articles.

1. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.;Soriano;AIDS,2007

2. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.;Torriani;N Engl J Med,2004

3. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C.;Loustaud-Ratti;Hepatology,2008

4. The use of ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.;Aguilar Marucco;J Antimicrob Chemother,2008

5. Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chromatography.;Svensson;Ther Drug Monit,2000

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients;Antimicrobial Agents and Chemotherapy;2014-06-30

2. Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment;Therapeutic Drug Monitoring;2012-12

3. Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV;Journal of Antimicrobial Chemotherapy;2012-03-05

4. Pharmacological exposure to ribavirin: A key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment;Digestive and Liver Disease;2011-11

5. Current treatment for chronic hepatitis C virus/HIV-infected individuals;Current Opinion in HIV and AIDS;2011-11